374794-75-9

Basic information

• Product Name: tert-butyl (3R,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate
• Synonyms: tert-butyl (3R,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate;Trans-3-Hydroxy-4-Methylpiperidine-1-Carboxylic Acid Tert-Butyl Ester;tert-butyl (3S,4R)-3-hydroxy-4-methylpiperidine-1-carboxylate;tert-butyl (3R,4S)-3-hydroxy-4-methylpiperidine-1-carboxylate;Trans-tert-butyl 3-hydroxy-4-methylpiperidine-1-carboxylate;Trans-3-Hydroxy-4-Methylpiperidine-1-Carboxylic Acid Tert-Butyl Ester(WX642013)
• CAS NO: 374794-75-9
• Molecular Formula: C11H21NO3
• Molecular Weight: 215.28934
• Mol File: 374794-75-9.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 301.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.067±0.06 g/cm3(Predicted)
• PKA: 14.76±0.40(Predicted)
• CAS DataBase Reference: tert-butyl (3R,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (3R,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate(374794-75-9)
• EPA Substance Registry System: tert-butyl (3R,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate(374794-75-9)

Safety Data

• Hazardous Substances Data: 374794-75-9(Hazardous Substances Data)

Usage

General Description

Tert-butyl (3R,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate is a chemical compound that belongs to the class of piperidine derivatives. It is a colorless liquid with a molecular formula C12H23NO3 and a molecular weight of 229.31 g/mol. tert-butyl (3R,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals due to its ability to modify the structure and properties of organic molecules. Additionally, tert-butyl (3R,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate has potential applications in the field of medicinal chemistry, particularly in the development of new drugs for the treatment of neurological disorders and cancer.

Upstream product

• 176966-86-2 tert-butyl (3S,4R)-3-(tert-butyldiphenylsilyloxy)-4-methyl-piperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 24211-54-9 (S)-5-hydroxypiperidin-2-one 
• 176966-76-0 (5S)-5-tert-butyldiphenylsilyloxy-piperidine-2-one 
• 176966-78-2 tert-butyl (5S)-5-(tert-butyldiphenylsilyloxy)-3,4-dehydro-piperidine-2-one-1-carboxylate 
• 176966-77-1 tert-butyl (5S)-5-tert-butyldiphenylsilyloxy-piperidine-2-one-1-carboxylate 
• 176966-80-6 tert-butyl (5S)-5-(tert-butyldiphenylsilyloxy)-4-methyl-2H-2-oxo-5,6-dihydro-piperidine-1-carboxylate 
• 374794-74-8 (trans)-3-hydroxy-4-methyl-piperidine hydrochloride 
• 374822-48-7 C₆H₁₃NO 
• 384338-20-9 (rac, trans)-1-benzyl-4-methyl-piperidin-3-ol 
• 1188264-78-9 rac-tert-butyl (3S,4R)-3-hydroxy-4-methylpiperidine-1-carboxylate 
• 1188264-78-9 (rac, cis)-3-hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 81474-43-3 (4R,5S)-5-(hydroxymethyl)-4-methyldihydrofuran-2(3H)-one 
• 88424-25-3 methyl (±)-(3-oxiran-2-yl)butanoate 

Downstream Products

• 37835-47-5 rac-(3S,4R)-1,4-dimethylpiperidin-3-ol 
• 374794-77-1 tert-butyl 4-methyl-3-oxopiperidine-1-carboxylate 
• 477600-74-1 tert-butyl (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate 
• 1259404-17-5 tasocitinib 

Relevant articles and documents

Synthesis of key intermediate for (+)-tofacitinib through CoIII(salen)-catalyzed two stereocentered hydrolytic kinetic resolution of (±)-methyl-3-(oxiran-2-yl)butanoate

An enantiopure piperidine, a key intermediate for the synthesis of (+)-tofacitinib, has been achieved in high optical purity (98% ee) from readily available crotyl alcohol. The key steps involved is a CoIII(salen)-OAc-catalyzed two stereocentered hydrolytic kinetic resolution of (±)-methyl-3-(oxiran-2-yl)butanoate.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.